Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Dec;58(6):1022-36.
doi: 10.1053/j.ajkd.2011.08.009. Epub 2011 Oct 21.

CKD-mineral and bone disorder: core curriculum 2011

Ranjani N Moorthi  1 , Sharon M Moe
Affiliations

CKD-mineral and bone disorder: core curriculum 2011

Ranjani N Moorthi et al. Am J Kidney Dis. 2011 Dec.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Regulation of Serum Phosphorus
A solid line indicates stimulation; a dashed line indicates inhibition. Adapted with permission of Elsevier from Moe SM, Sprague SM. Mineral bone disorders in chronic kidney disease. In: Brenner and Rector’s The Kidney, 8th ed. Philadelphia, PA: WB Saunders Company; 2007:1784–1807.
Figure 2
Figure 2. Overview of Vitamin D Metabolism
Adapted with permission of Elsevier from Moe SM, Sprague SM. Mineral bone disorders in chronic kidney disease. In: Brenner and Rector’s The Kidney, 8th ed. Philadelphia, PA: WB Saunders Company; 2007:1784–1807.
Figure 3
Figure 3. Assays for parathyroid h ormone (PTH)
The intact PTH molecule is composed of 84 amino acids; different regions of the protein are targeted by first through third generation assays. Mid/C-PTH, mid/carboxyl terminus of PTH; N-PTH, amino terminus of PTH; RIA, radioimmunoassay. Reproduced with permission of Elsevier from Moe SM, Sprague SM. Mineral bone disorders in chronic kidney disease. In: Brenner and Rector’s The Kidney, 8th ed. Philadelphia, PA: WB Saunders Company; 2007:1784–1807.
Figure 4
Figure 4. Turnover Mineraliz ation Volume (TMV) Classification System for Bone Histomorphometry
The TMV system provides more information than the previously used classification scheme. Each axis represents one of the descriptors in the TMV classification: turnover (from low to high), mineralization (from normal to abnormal), and bone volume (from low to high). Individual patient parameters can be plotted on the graph, or means and ranges of grouped data can be shown. For example, many patients with renal osteodystrophy cluster in areas shown by the bars. The red bar (OM, osteomalacia) was previously described as low-turnover bone with abnormal mineralization. The bone volume may be low to medium, depending on the severity and duration of the process and other factors that affect bone. The green bar (AD, adynamic bone disease) was previously described as low-turnover bone with normal mineralization, and the bone volume in this example is at the lower end of the spectrum, but other patients with normal mineralization and low turnover will have normal bone volume. The yellow bar (mild HPT, mild hyperparathyroid-related bone disease) and purple bar (OF, osteitis fibrosa or advanced hyperparathyroid-related bone disease) were previously considered distinct categories, but in actuality represent a range of abnormalities along a continuum of medium to high turnover, and any bone volume depending on the duration of the disease process. Finally, the blue bar (MUO, mixed uremic osteodystrophy) is variably defined internationally. In the present graph, it is depicted as high-turnover, normal bone volume, with abnormal mineralization. In summary, the TMV classification system more precisely describes the range of pathologic abnormalities that can occur in patients with CKD. Reproduced with permission of Nature Publishing Group from Figure 1 in Moe et al. Kidney Int. 2006;69(11):1945–53.
Figure 5
Figure 5. Pathogenesis of Vascular Calcification
Normally, mesenchymal stem cells differentiate to adipocytes, osteoblasts, chondrocytes, and vascular smooth muscle cells (VSMC). In the setting of CKD, diabetes, aging, inflammation, and multiple other toxins, these VSMC can dedifferentiate or transform into osteo/chondrocytic-like cells by upregulation of transcription factors such as RUNX-2 and MSX2. These transcription factors are critical for normal bone development and thus their upregulation in VSMC is indicative of a phenotypic switch. These osteo/chondrocytic-like VSMC then become calcified in a process similar to bone formation. These cells lay down collagen and noncollagenous proteins in the intima or media and incorporate calcium and phosphorus into matrix vesicles to initiate mineralization and further mineralize into hydroxyapatite. The overall positive calcium and phosphorus balance of most dialysis patients feeds both the cellular transformation and the generation of matrix vesicles. In addition, the extremes of bone turnover in chronic kidney disease (low and high or adynamic and hyperparathyroid bone, respectively) will increase the available calcium and phosphorus by altering the bone content of these minerals. Ultimately, whether an artery calcifies or not depends on the strength of the army of inhibitors (I) standing by in the circulation (fetuin A) and in the arteries (PPI = pyrophosphate, MGP = matrix Gla protein, and OP = osteopontin as examples). Reproduced with permission of the American Society of Nephrology from Figure 1 in Moe et al. J Am Soc Nephrol. 2008;19:213–216.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) Kidney Int. 2006 Jun;69(11):1945–1953. - PubMed
    1. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Kidney Int Suppl. 2009 Aug;113:S1–S130. - PubMed
    1. Moe SM, Drueke T, Lameire N, Eknoyan G. Chronic kidney disease-mineral-bone disorder: a new paradigm. Adv Chronic Kidney Dis. 2007 Jan;14(1):3–12. - PubMed
    1. Moe SM, Sprague SM. Brenner and Rector’s The Kidney. 8. WB Saunders Company; Philadelphia, PA: 2007. Chapter 52: Mineral bone disorders in chronic kidney disease; pp. 1784–1807.
    1. Moe SM. In: Chapter 8: Chronic Kidney Disease, Dialysis, and Transplantation. 3. Himmelfarb J, Sayegh M, editors. Elsevier Saunders; Philadelphia: 2010. pp. 98–114.

MeSH terms